SG11202100385YA - Use of riluzole prodrugs to treat alzheimer's disease - Google Patents

Use of riluzole prodrugs to treat alzheimer's disease

Info

Publication number
SG11202100385YA
SG11202100385YA SG11202100385YA SG11202100385YA SG11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA SG 11202100385Y A SG11202100385Y A SG 11202100385YA
Authority
SG
Singapore
Prior art keywords
patient
administered
riluzole
disease
riluzole prodrug
Prior art date
Application number
SG11202100385YA
Other languages
English (en)
Inventor
Vladimir Coric
Robert Berman
Irfan Qureshi
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of SG11202100385YA publication Critical patent/SG11202100385YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202100385YA 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease SG11202100385YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Publications (1)

Publication Number Publication Date
SG11202100385YA true SG11202100385YA (en) 2021-02-25

Family

ID=69181140

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100385YA SG11202100385YA (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Country Status (14)

Country Link
US (1) US12161633B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823616A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021530543A (cg-RX-API-DMAC7.html)
KR (1) KR20210034621A (cg-RX-API-DMAC7.html)
CN (1) CN112469408A (cg-RX-API-DMAC7.html)
AU (1) AU2019310013B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000768A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107215A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190308A1 (cg-RX-API-DMAC7.html)
IL (1) IL280177B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021000515A (cg-RX-API-DMAC7.html)
PH (1) PH12021550043A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100385YA (cg-RX-API-DMAC7.html)
WO (1) WO2020023324A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299301A (en) * 2020-06-24 2023-02-01 Biohaven Therapeutics Ltd Compositions and methods for the treatment of obsessive compulsive disorder
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
BR112023016690A2 (pt) * 2021-02-22 2023-11-14 Univ Yale Degradadores bifuncionais direcionados e métodos usando os mesmos
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275525B2 (en) * 2000-06-14 2007-04-26 Medarex, Inc. Tripeptide prodrug compounds
EP1814558B1 (en) * 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
US10258611B2 (en) * 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
HRP20220237T1 (hr) * 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
US12029731B2 (en) * 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
US10751345B2 (en) * 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease

Also Published As

Publication number Publication date
AU2019310013B2 (en) 2025-01-02
WO2020023324A1 (en) 2020-01-30
MX2021000515A (es) 2021-06-08
IL280177A (en) 2021-03-01
IL280177B1 (en) 2024-09-01
CA3107215A1 (en) 2020-01-30
JP2021530543A (ja) 2021-11-11
EP3823616A1 (en) 2021-05-26
EP3823616A4 (en) 2022-05-04
NZ772009A (en) 2026-02-27
BR112021000768A2 (pt) 2021-05-11
AU2019310013A1 (en) 2021-02-11
PH12021550043A1 (en) 2021-09-20
KR20210034621A (ko) 2021-03-30
US12161633B2 (en) 2024-12-10
CN112469408A (zh) 2021-03-09
MX2024010655A (es) 2024-09-11
IL280177B2 (en) 2025-01-01
EA202190308A1 (ru) 2021-05-19
US20210290599A1 (en) 2021-09-23
JP2025093952A (ja) 2025-06-24

Similar Documents

Publication Publication Date Title
IL280177A (en) Use of riluzole prodrugs to treat Alzheimer's disease
IL276493A (en) Carbidopa and L-dopa prodrugs and methods for use in the treatment of Parkinson's disease
IL271046A (en) Compounds for treating huntington's disease
IL265528A (en) aav therapy for Huntington's disease
IL274648A (en) Promote new catecholamine drugs for use in the treatment of Parkinson's disease
IL254030B (en) Use of pyridofidine to improve cognitive function and to treat Alzheimer's disease
EP3562514A4 (en) GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE
IL275321A (en) Treatment of diseases associated with the expression of DUX4
IL274532A (en) Using the prodrug riluzole to treat ataxias
LT3463351T (lt) Parkinsono ligos gydymas
SG11202011187QA (en) Use of riluzole oral disintigrating tablets for treating diseases
IL280657A (en) Use of riluzole oral dissolving tablets to treat diseases
EP4277624A4 (en) USE OF RILUZOLE PRODRUGS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL290726A (en) Use of Brazicomb to treat Crohn's disease
PL3352742T3 (pl) Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona
HK40041745A (en) Use of riluzole prodrugs to treat alzheimer's disease
ES3065944T3 (en) Use of riluzole prodrugs to treat ataxias
HK40068889A (en) Use of brazikumab to treat crohn's disease
HK40037165A (en) Catecholamine prodrugs for use in the treatment of parkinson's disease
AU2017902307A0 (en) Treatment of alzheimer's disease
AU2017902309A0 (en) Treatment of alzheimer's disease
GB201511453D0 (en) Treatment of alzheimer's disease
GB201504144D0 (en) Treatment of Parkinson's disease